225Ac-LNC1011

N/A

Report date: 2026/02/11 20:01:36
NME

Base Information

Drug Name225Ac-LNC1011
Drug Alias Name225Ac-LNC1011225Ac-LNC-1011
ClassificationRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Nuclides > Actinium > 225AcRadiation-emitting products > Radionuclide Drug Conjugates +[4] 
Mechanisms of ActionProstate-Specific Membrane Antigen modulators
TargetsProstate-Specific Membrane Antigen
Therapy Area/IndicationsProstatic Neoplasms, Castration-ResistantProstatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesYantai Lannacheng Biotechnology Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesFirst Affiliated Hospital Of Fujian Medical UniversityYantai Lannacheng Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsProstatic Neoplasms, Castration-ResistantProstatic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A